Stoboclo: Uses, Dosage & Side Effects

What Is Stoboclo and What Is It Used For?

Stoboclo contains the active substance denosumab-bmwo, a fully human monoclonal antibody of the immunoglobulin G2 (IgG2) subclass. It is produced in genetically engineered Chinese hamster ovary (CHO) cells using recombinant DNA technology and undergoes a highly controlled purification process to ensure consistent quality and potency. Stoboclo is a biosimilar of Prolia (reference product manufactured by Amgen) and was approved by the U.S. Food and Drug Administration (FDA) in March 2025 as one of the first interchangeable biosimilars to the originator denosumab. The biosimilar designation is granted only after comprehensive comparative analytical, non-clinical, pharmacokinetic, pharmacodynamic, and clinical studies demonstrate that there are no clinically meaningful differences between the biosimilar and the reference product in terms of safety, purity, and potency.

The clinical importance of denosumab rests on its central role in modulating the RANK/RANKL/OPG signaling axis, the master regulator of osteoclast biology. Healthy bone is continuously remodeled through a finely balanced interplay between bone-forming osteoblasts and bone-resorbing osteoclasts. Receptor activator of nuclear factor kappa-B ligand (RANKL) is a transmembrane protein expressed by osteoblasts, osteocytes, and activated T lymphocytes. When RANKL binds to its receptor RANK on osteoclast precursor cells and mature osteoclasts, it triggers intracellular signaling that drives osteoclast differentiation, activates bone-resorbing activity, and prolongs osteoclast survival. In conditions such as postmenopausal estrogen deficiency, chronic glucocorticoid excess, androgen deprivation, and aromatase inhibition, RANKL expression is upregulated, tipping the bone remodeling balance toward excessive resorption and progressive bone loss.

Denosumab-bmwo functions as a pharmacological analogue of osteoprotegerin (OPG), the body’s endogenous decoy receptor for RANKL. By binding to RANKL with high affinity and specificity, Stoboclo prevents RANKL from interacting with RANK on osteoclast surfaces. The downstream effects are profound: inhibition of osteoclast differentiation from hematopoietic precursors, suppression of bone-resorbing activity in mature osteoclasts, and promotion of osteoclast apoptosis. Following a single 60 mg subcutaneous injection, serum markers of bone resorption (such as C-telopeptide, CTX) decrease by approximately 85% within 3 days and remain suppressed for approximately 6 months, at which point the next dose is typically administered. The net clinical result is sustained suppression of bone turnover, progressive increases in bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and distal radius, and a clinically meaningful reduction in fracture risk.

Stoboclo is indicated for the following clinical conditions in adult patients:

• Treatment of postmenopausal women with osteoporosis at high risk for fracture: This is the primary and most common indication, defined as women with a history of osteoporotic fracture, multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. Denosumab has been shown to reduce the incidence of vertebral, non-vertebral, and hip fractures in this population.
• Treatment to increase bone mass in men with osteoporosis at high risk for fracture: Osteoporosis in men is underdiagnosed and undertreated, yet men account for approximately one-third of hip fractures worldwide and have higher post-fracture mortality than women. Denosumab has been shown to significantly increase BMD in men with osteoporosis.
• Treatment of glucocorticoid-induced osteoporosis (GIO): Adults initiating or continuing long-term systemic glucocorticoid therapy (≥7.5 mg of prednisone equivalent daily for at least 3 months) at high risk of fracture. Glucocorticoid therapy is the most common cause of drug-induced osteoporosis.
• Treatment to increase bone mass in men with non-metastatic prostate cancer at high risk for fracture receiving androgen deprivation therapy (ADT): ADT causes rapid bone loss and increases fracture risk; denosumab has been shown to reduce the incidence of new vertebral fractures in this population.
• Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer: Aromatase inhibitors accelerate bone loss by suppressing estrogen production; denosumab preserves BMD and reduces fracture risk in these patients.

The efficacy of denosumab in postmenopausal osteoporosis was established by the landmark FREEDOM trial (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months), a pivotal 3-year randomized, double-blind, placebo-controlled study that enrolled 7,868 postmenopausal women aged 60–90 years with osteoporosis. Compared with placebo, denosumab 60 mg every 6 months produced a 68% relative risk reduction in new vertebral fractures (relative risk 0.32, 95% CI 0.26–0.41), a 40% reduction in hip fractures (hazard ratio 0.60, 95% CI 0.37–0.97), and a 20% reduction in non-vertebral fractures (hazard ratio 0.80, 95% CI 0.67–0.95). The FREEDOM extension study followed participants for up to 10 years of continuous denosumab therapy and demonstrated sustained BMD gains, persistently low fracture rates, and a favorable long-term safety profile.

Additional clinical evidence supports the use of denosumab in specific populations. The ADAMO trial showed significant BMD gains in men with osteoporosis. The HALT trial in men with non-metastatic prostate cancer receiving ADT demonstrated a 62% reduction in new vertebral fractures. A randomized trial in women receiving adjuvant aromatase inhibitor therapy for breast cancer showed significant preservation of BMD at multiple skeletal sites. Because Stoboclo is a biosimilar of Prolia, its clinical efficacy is extrapolated from this extensive body of evidence on the reference product, supplemented by comparative pharmacokinetic, pharmacodynamic, and efficacy studies specifically for the biosimilar.

What Should You Know Before Taking Stoboclo?

Contraindications

Stoboclo is contraindicated in patients with pre-existing hypocalcemia. Hypocalcemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. This is a critical safety requirement because denosumab’s potent inhibition of bone resorption markedly reduces the physiological release of calcium from the skeletal reservoir, which can unmask or exacerbate latent hypocalcemia. Severe hypocalcemia can lead to potentially life-threatening complications, including prolonged QT interval on electrocardiogram, cardiac arrhythmias, seizures, tetany, laryngospasm, and muscle spasms. Patients at particular risk include those with severe renal impairment (creatinine clearance <30 mL/min), those receiving dialysis, those with hypoparathyroidism, prior thyroid or parathyroid surgery, malabsorption syndromes, excision of the small intestine, or a history of severe vitamin D deficiency.

Stoboclo is also contraindicated in patients with a history of serious hypersensitivity reaction to denosumab or to any of the excipients in the formulation. Serious allergic reactions, including anaphylaxis, facial and throat swelling, rash, and dyspnea, have been reported with denosumab products. Because denosumab-bmwo and Prolia share the identical active molecule, a prior hypersensitivity reaction to one is a contraindication to the other. Stoboclo is also contraindicated during pregnancy due to documented risks of fetal harm based on animal reproduction data and the drug’s mechanism of action.

Before starting Stoboclo, your healthcare provider should perform a comprehensive baseline assessment including measurement of serum calcium, 25-hydroxyvitamin D, serum creatinine and estimated glomerular filtration rate (eGFR), phosphate, and parathyroid hormone if clinically indicated. A thorough dental examination with appropriate preventive dentistry is recommended prior to treatment, particularly for patients with risk factors for osteonecrosis of the jaw. Serum calcium should be monitored within 14 days of the first injection in patients at high risk of hypocalcemia and periodically thereafter.

Warnings and Precautions

Hypocalcemia: Stoboclo can cause severe symptomatic hypocalcemia, and fatal cases have been reported in post-marketing experience with denosumab. The risk is substantially increased in patients with impaired calcium regulation, including those with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), patients on dialysis, patients with hypoparathyroidism, and patients with malabsorptive conditions. Adequate intake of calcium (at least 1,000 mg/day) and vitamin D (at least 400 IU/day, often 800–2,000 IU/day in deficient patients) is essential throughout therapy. Symptomatic hypocalcemia, including seizures, paresthesias, tetany, and arrhythmias, requires prompt evaluation and treatment.

Serious infections: In clinical trials of denosumab for osteoporosis, infections leading to hospitalization were reported more frequently in the denosumab group compared with placebo (approximately 4.1% vs 3.4%), with a particular increase in serious skin infections (predominantly cellulitis and erysipelas) and infections of the abdomen, urinary tract, and ear. Patients receiving concomitant immunosuppressive therapy or with conditions that impair immune function are at heightened risk. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of cellulitis (redness, warmth, tenderness, swelling of the skin, fever) or other serious infections.

Dermatologic reactions: Dermatitis, eczema, pruritus, and rash, including severe cases, have been reported with denosumab. Most skin reactions are mild to moderate and do not require discontinuation. However, in severe or persistent cases, or when skin reactions are accompanied by other signs of hypersensitivity, discontinuation of Stoboclo should be considered in consultation with the prescribing physician.

Osteonecrosis of the jaw (ONJ): ONJ is a well-recognized but rare adverse effect of anti-resorptive therapy, including denosumab. It manifests as jaw pain, non-healing oral lesions, osteomyelitis, bone erosion, exposed bone, tooth or periodontal infection, toothache, gingival ulceration, gingival erosion, or slow healing after dental procedures. Known risk factors include invasive dental procedures (tooth extraction, dental implants, oral surgery), poor oral hygiene, ill-fitting dentures, pre-existing dental disease, concomitant corticosteroids or chemotherapy, angiogenesis inhibitors, smoking, diabetes mellitus, and anemia. A dental examination with appropriate preventive dentistry should be performed prior to starting Stoboclo in patients with risk factors. During treatment, patients should maintain meticulous oral hygiene, receive routine dental check-ups, and avoid elective invasive dental procedures when possible. If invasive dental procedures become necessary, they should be planned in consultation with the prescriber and dentist, with consideration given to the timing within the dosing cycle.

Atypical femoral fractures: Atypical low-energy or low-trauma fractures of the femoral shaft have been reported with denosumab, although they are rare. These fractures may occur anywhere along the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in configuration, often bilateral, and preceded by weeks to months of prodromal thigh, hip, or groin pain. Any patient presenting with new thigh, hip, or groin pain on denosumab therapy should be evaluated promptly with imaging to rule out an incomplete femoral fracture. If an atypical femoral fracture is confirmed, discontinuation of Stoboclo should be considered based on individual benefit–risk assessment.

Hypersensitivity reactions: Clinically significant hypersensitivity reactions, including anaphylaxis, angioedema, facial swelling, dyspnea, urticaria, pruritus, rash, and hypotension, have occurred with denosumab. If a severe allergic reaction occurs, Stoboclo must be discontinued permanently and appropriate emergency medical treatment instituted.

Renal impairment: Patients with severe renal impairment (creatinine clearance <30 mL/min) or receiving dialysis are at increased risk of developing severe hypocalcemia with denosumab. No dose adjustment is required, but these patients require more intensive monitoring of serum calcium and may require higher doses of calcium and active vitamin D supplementation.

Pregnancy and Breastfeeding

Stoboclo is not recommended for use during pregnancy. There are no adequate, well-controlled studies of denosumab in pregnant women. Animal reproduction studies have demonstrated significant reproductive toxicity, including increased stillbirths, postnatal mortality, absent peripheral lymph nodes, abnormal bone growth, reduced bone strength, and reduced neonatal growth in offspring exposed to denosumab in utero. The mechanism of action — RANKL inhibition — has implications for fetal bone development, tooth development, and immune system development, because RANKL is essential for the formation of bone marrow cavities, dental lamina, and lymph nodes during embryogenesis. Females of reproductive potential should be advised to use effective contraception during therapy and for at least 5 months after the last dose of Stoboclo. Pregnancy should be excluded before initiating treatment.

Breastfeeding is not recommended during treatment with Stoboclo. It is not known whether denosumab is present in human breast milk. However, endogenous immunoglobulins and other antibodies are transferred into milk, and the potential for adverse effects on the breastfed infant — particularly effects on developing bone and the immune system — cannot be excluded. Women who wish to breastfeed should discuss the risks and benefits with their healthcare provider and may need to either discontinue breastfeeding or defer Stoboclo therapy. There are presently no data to inform a washout period for breastfeeding after the last dose of Stoboclo.

Fertility: There are no data on the effect of denosumab on human fertility. In animal studies, denosumab had no effect on female fertility or on male reproductive organs. Long-term effects on human fertility have not been studied.

How Does Stoboclo Interact with Other Drugs?

Denosumab-bmwo is a fully human IgG2 monoclonal antibody that is cleared primarily through the reticuloendothelial system via general protein catabolism, rather than through hepatic cytochrome P450 (CYP) enzymes or renal excretion of intact drug. Because monoclonal antibodies do not interact with CYP isoenzymes, traditional pharmacokinetic drug-drug interactions (such as those commonly observed with small-molecule drugs that induce or inhibit CYP3A4, CYP2D6, or CYP2C9) are not expected with Stoboclo. Formal dedicated drug-interaction studies have not been conducted with denosumab-bmwo, but extensive post-marketing experience with the reference product across millions of patient-years of exposure has not identified clinically meaningful pharmacokinetic interactions.

Despite the absence of pharmacokinetic interactions, several important pharmacodynamic interactions and clinical considerations merit attention when prescribing Stoboclo. These include interactions with other anti-resorptive agents, drugs that may increase the risk of osteonecrosis of the jaw, immunomodulatory drugs that may compound infection risk, and essential supportive co-therapies such as calcium and vitamin D.

Major Interactions

The most clinically significant interaction concern involves the concurrent use of Stoboclo with bisphosphonates. Both drug classes suppress osteoclast-mediated bone resorption, although through distinct mechanisms: bisphosphonates bind to hydroxyapatite and directly inhibit osteoclast function and survival, while denosumab inhibits RANKL signaling upstream of osteoclast formation. The theoretical concern with combined therapy is over-suppression of bone turnover, which could increase the risk of hypocalcemia, atypical femoral fractures, and osteonecrosis of the jaw. Clinical guidelines from major osteoporosis societies (IOF, NICE, NAMS) consistently recommend against simultaneous use of these two drug classes. However, sequential therapy is an important and validated clinical strategy: a bisphosphonate is commonly initiated approximately 6–9 months after the last denosumab dose to prevent the rebound bone loss that occurs after denosumab discontinuation.

The risk of serious infections, particularly cellulitis, warrants careful consideration when Stoboclo is prescribed alongside other immunosuppressive therapies. In the FREEDOM trial, serious infections requiring hospitalization occurred in 4.1% of denosumab-treated patients compared with 3.4% of placebo-treated patients, with skin infections being disproportionately represented. RANKL is expressed not only on osteoblasts but also on activated T lymphocytes and dendritic cells, where it plays a role in the immune synapse and lymph node development. While the clinical significance of this immunomodulation appears modest in immunocompetent patients, patients on concurrent methotrexate, azathioprine, mycophenolate, calcineurin inhibitors, or biologic DMARDs should be monitored carefully for signs of infection.

The combined risk of osteonecrosis of the jaw is a critical consideration for patients receiving Stoboclo alongside corticosteroids, chemotherapy, or angiogenesis inhibitors. These agents independently increase ONJ risk, and their additive effect with potent anti-resorptive therapy can be substantial. In cancer patients, where the combination of denosumab with chemotherapy and corticosteroids is common, structured dental surveillance before and during therapy is strongly recommended, including baseline dental examination, treatment of active dental disease, and avoidance of invasive dental procedures when feasible.

Minor Interactions

Stoboclo does not appear to interact significantly with the vast majority of commonly prescribed medications. Clinical trial participants took a wide array of concomitant medications — including antihypertensives, statins, proton pump inhibitors, selective serotonin reuptake inhibitors, oral hypoglycemic agents, anticoagulants, and thyroid hormone replacement — without evidence of clinically meaningful pharmacokinetic or pharmacodynamic interactions. Hormone replacement therapy and selective estrogen receptor modulators (raloxifene, bazedoxifene) have been used concurrently with denosumab in clinical practice without identified safety signals, although the incremental benefit of adding denosumab to these therapies has not been formally established.

Patients should always provide their healthcare provider with a complete list of all medications, over-the-counter products, herbal supplements, and vitamins they are taking before starting Stoboclo. While traditional pharmacokinetic interactions are unlikely, the pharmacodynamic and additive safety considerations outlined above are clinically important and should inform monitoring and patient education strategies.

What Is the Correct Dosage of Stoboclo?

Stoboclo is supplied as a ready-to-use sterile, preservative-free, clear, colorless to slightly yellow solution in a single-use pre-filled syringe containing 60 mg of denosumab-bmwo in 1 mL. The fixed-dose regimen of 60 mg every 6 months is the same for all approved indications and does not require adjustment based on body weight, age, sex, race, or renal function. This simple, flat-dose regimen eliminates the need for therapeutic drug monitoring, complex dose calculations, or adjustments during treatment and is one of the principal practical advantages of denosumab therapy compared with other osteoporosis medications.

Administration requires proper technique to ensure optimal safety and efficacy. Before injection, Stoboclo should be removed from refrigeration and allowed to reach room temperature (up to 25°C / 77°F) for approximately 15–30 minutes. The syringe should not be warmed by any other means and should not be shaken. The solution should be visually inspected for particulates and discoloration prior to use. The injection is administered subcutaneously into the upper arm, upper thigh, or abdomen, using the pre-filled syringe’s integrated needle-safety device. The injection site should not be used if there are signs of bruising, tenderness, or redness. After administration, the injection site should be monitored briefly for signs of a hypersensitivity reaction.

Adults

Children and Adolescents

Stoboclo 60 mg is not approved for use in children or adolescents under 18 years of age. The safety and efficacy of denosumab at the 60 mg dose have not been established in the pediatric population. RANKL plays essential roles in skeletal modeling, immune system development, lymph node formation, and tooth eruption during growth, so the long-term consequences of RANKL inhibition in a developing skeleton are not fully understood. A higher-dose denosumab product (120 mg, marketed under a different trade name) has been studied in skeletally mature adolescents with giant cell tumor of bone, but this represents a different indication, dose, and product. Stoboclo should not be used in pediatric patients outside of approved clinical research protocols.

Elderly

No dose adjustment is required for elderly patients. In the FREEDOM trial, approximately one-third of enrolled patients were aged 75 years or older, and the efficacy and safety profile of denosumab was consistent across age groups. There was no increased incidence of serious adverse events in elderly compared with younger participants. Stoboclo offers particular practical advantages in elderly patients, as its 6-monthly subcutaneous administration avoids the stringent administration requirements of oral bisphosphonates (30-minute fasting, remaining upright, risk of esophagitis) and the intravenous access requirements of zoledronic acid. In very frail elderly patients, careful attention to calcium/vitamin D adequacy, renal function, and dental status remains essential.

Renal impairment: No dose adjustment is required for patients with any degree of renal impairment. However, patients with severe renal impairment (creatinine clearance <30 mL/min) or those receiving dialysis are at elevated risk of developing symptomatic hypocalcemia due to impaired vitamin D activation (conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D occurs in the kidney) and altered calcium handling. These patients require intensive monitoring of serum calcium — typically within 2 weeks of the first dose — and may require active vitamin D (calcitriol) supplementation rather than cholecalciferol alone, with corresponding calcium supplementation. Pre-treatment correction of hypocalcemia and vitamin D deficiency is essential.

Hepatic impairment: No dose adjustment is required for patients with hepatic impairment. As denosumab is not metabolized by the liver, hepatic disease does not affect its disposition. Formal studies in patients with hepatic impairment have not been conducted.

Missed Dose

If a scheduled dose of Stoboclo is missed or delayed, the injection should be administered as soon as practically possible. After the missed dose is given, subsequent doses should be scheduled every 6 months from the date of the most recent injection, not from the originally scheduled date. The pharmacodynamic effects of denosumab begin to wane by approximately 6 months after the last injection, and bone turnover markers rise rapidly to levels above pre-treatment baseline by 9–12 months, with progressive loss of BMD. Delays of a few weeks beyond the scheduled 6-month interval have minimal clinical impact, but longer delays (2 months or more) may begin to reverse BMD gains and increase fracture risk. Patients should be counseled about the importance of adherence to the 6-monthly dosing schedule.

Overdose

There is no clinical experience with acute overdose of denosumab. In early clinical development studies, denosumab was administered at doses up to 180 mg every 4 weeks (three times the recommended dose at 50% higher frequency) without identification of dose-limiting toxicity. There is no specific antidote for denosumab overdose, and because of its long half-life (approximately 26 days) and receptor-mediated mechanism, there is no effective method for accelerating its elimination. Management of overdose is supportive, with careful monitoring for hypocalcemia and other expected pharmacological effects. Serum calcium should be measured frequently in the weeks following the overdose, and calcium supplementation should be intensified if needed.

What Are the Side Effects of Stoboclo?

The safety profile of denosumab has been extensively characterized through multiple large-scale randomized controlled trials, their long-term extension studies, and more than a decade of post-marketing pharmacovigilance. The pivotal FREEDOM trial and its 10-year extension enrolled more than 7,800 postmenopausal women with osteoporosis, providing robust long-term safety data covering the typical duration of clinical use. As Stoboclo is a biosimilar, its safety profile is expected to closely mirror that of the reference product Prolia, supplemented by comparative clinical and pharmacovigilance data specifically for denosumab-bmwo.

Adverse reactions reported with denosumab therapy are categorized below by frequency according to the internationally recognized MedDRA convention. It is important to note that most side effects are mild to moderate in severity and do not require discontinuation of therapy, while serious adverse events are rare but warrant immediate medical attention.

Musculoskeletal pain is the most frequently reported adverse effect associated with denosumab therapy. In the FREEDOM trial, back pain was reported in 34.7% of denosumab-treated patients compared with 34.6% of placebo-treated patients, indicating that the background rate is high in the target population, but post-marketing reports have also identified cases of severe, sometimes disabling musculoskeletal pain that can develop days to months after the first or subsequent doses. This severe pain is characterized by diffuse or migratory aching, can affect multiple body regions, and may resolve with discontinuation of therapy. The mechanism is not fully understood but may involve immune-mediated musculoskeletal inflammation.

Infections, particularly of the urinary tract and upper respiratory system, are reported somewhat more frequently in denosumab-treated patients than in placebo-treated patients in clinical trials. Serious infections requiring hospitalization, including cellulitis, erysipelas, endocarditis, abdominal infections, and urinary tract infections, occurred in 4.1% of denosumab versus 3.4% of placebo recipients in the FREEDOM trial. RANKL plays a role in immune function through effects on dendritic cell survival and lymphocyte interactions, which may contribute to this modest excess risk. Patients should be educated to recognize the early signs of cellulitis (localized redness, warmth, tenderness, swelling, with or without fever) and seek prompt medical evaluation.

Hypocalcemia is an anticipated pharmacological consequence of potent anti-resorptive therapy. In clinical trials of patients with normal baseline calcium and adequate supplementation, clinically significant hypocalcemia was uncommon (approximately 0.4%). However, in post-marketing use — particularly in patients with advanced chronic kidney disease, those on dialysis, patients with hypoparathyroidism, and patients with malabsorptive conditions — cases of severe, symptomatic, and rarely fatal hypocalcemia have been reported. Recent evidence has highlighted that patients on dialysis are at particularly high risk; some expert bodies now recommend against the use of denosumab in this population unless specific expertise and monitoring are available.

Osteonecrosis of the jaw and atypical femoral fractures are rare but serious complications of long-term anti-resorptive therapy. The absolute risk is low (approximately 1–2 cases per 10,000 patient-years for ONJ in osteoporosis doses, higher in oncology doses), but the potential severity warrants careful patient selection, dental surveillance, and patient education. Risk increases with cumulative duration of therapy, concomitant glucocorticoid or chemotherapy use, invasive dental procedures, and pre-existing dental disease.

How Should You Store Stoboclo?

Proper storage of Stoboclo is essential to maintain the stability, potency, and safety of the biological product. As a protein-based monoclonal antibody, denosumab-bmwo is sensitive to temperature extremes, physical agitation, and light exposure. Any of these stressors can induce protein denaturation, aggregation, fragmentation, or loss of biological activity, which may compromise efficacy and potentially increase immunogenicity (formation of anti-drug antibodies).

The recommended storage conditions for Stoboclo are:

• Refrigeration: Store the pre-filled syringe in a refrigerator at 2–8°C (36–46°F). This is the primary long-term storage condition for the duration of the product’s shelf life.
• Protect from light: Keep the syringe in its original outer carton until the time of use to shield the solution from light exposure, which can accelerate protein degradation.
• Do not freeze: Freezing causes irreversible damage to the three-dimensional structure of the monoclonal antibody. If Stoboclo has been frozen, the syringe must be discarded and must not be used, even if it appears visually normal after thawing.
• Allow to reach room temperature before use: Remove Stoboclo from refrigeration approximately 15–30 minutes before administration to allow it to reach room temperature (up to 25°C / 77°F). This reduces injection-site discomfort associated with cold-solution administration.
• Do not warm artificially: Do not use hot water, microwave ovens, or other heating methods to warm the syringe, as localized overheating can denature the protein.
• Do not shake: Vigorous shaking can cause protein aggregation and foaming, both of which may reduce biological activity and increase immunogenic potential. Handle the syringe gently.
• Visual inspection: Before injection, inspect the solution visually. It should appear clear, colorless to slightly yellow, and essentially free of visible particles. Do not use if the solution is cloudy, discolored, or contains visible particulate matter.
• Expiry date: Do not use Stoboclo after the expiration date printed on the carton and syringe label. The expiration date represents the last date through which the manufacturer guarantees full potency and safety under recommended storage conditions.
• Storage after leaving refrigeration: Once removed from refrigeration and stored at room temperature, Stoboclo should be used within a defined window (refer to the prescribing information for the specific product; typically up to 14 days at room temperature in the original carton). After this time, the syringe must be discarded.

Keep Stoboclo out of the sight and reach of children. Used syringes must not be disposed of in household waste; they should be placed in a rigid sharps disposal container and disposed of in accordance with local regulations and the policies of your healthcare facility. Because Stoboclo is typically administered by a healthcare professional, the administration and disposal of the pre-filled syringe will generally be handled within the clinic or hospital setting. If self-administration is prescribed in specific circumstances, patients should be trained on proper injection technique, storage, and sharps disposal.

What Does Stoboclo Contain?

Stoboclo is a sterile, preservative-free, clear, colorless to slightly yellow solution provided in a single-dose, pre-filled syringe with an integrated needle-safety device. Understanding the complete composition of the product is important for healthcare providers assessing potential allergenic components and for patients with known sensitivities to specific excipients or food ingredients.

Active Ingredient

The active ingredient is denosumab-bmwo, a fully human immunoglobulin G2 (IgG2) monoclonal antibody with a molecular weight of approximately 147 kilodaltons (kDa). Denosumab-bmwo is structurally and functionally equivalent to the reference product denosumab. Each pre-filled syringe contains 60 mg of denosumab-bmwo in 1 mL of solution (60 mg/mL). The protein is produced by recombinant DNA technology in genetically engineered Chinese hamster ovary (CHO) cells using mammalian cell culture, and is purified through a multi-step chromatographic and filtration process to achieve high purity suitable for human administration.

Inactive Ingredients (Excipients)

The formulation contains the following excipients, which serve as stabilizers, buffers, tonicity agents, and surfactants to preserve the structural integrity and biological activity of the monoclonal antibody throughout its shelf life:

• Sorbitol: A sugar alcohol that serves as a stabilizer and tonicity agent. Sorbitol helps maintain osmotic balance and prevents protein aggregation during storage. Patients with hereditary fructose intolerance should discuss this with their doctor before injection, although the amount is small in a 1 mL dose.
• Glacial acetic acid: Used as a buffering agent to maintain the solution at the optimal pH range for protein stability (typically around pH 5.0–5.5).
• Sodium hydroxide: Used in small quantities to adjust the pH to the target formulation pH.
• Polysorbate 20: A non-ionic surfactant that prevents protein aggregation and adsorption to container surfaces during manufacturing, transport, and storage. Polysorbate 20 is generally well tolerated but can rarely cause hypersensitivity reactions.
• Water for injection: The sterile solvent vehicle for the formulation.

Stoboclo does not contain preservatives, latex in the syringe components, or any animal-derived ingredients beyond the CHO cell line used in production (the cell line itself is not present in the final product). The total sodium content per 60 mg dose is essentially negligible for patients on sodium-restricted diets. Patients with known hypersensitivity to any of the listed excipients should inform their healthcare provider before receiving the injection. Patients with hereditary fructose intolerance should discuss the sorbitol content with their doctor, although the quantity in a single 1 mL dose is very small.

Appearance and Presentation

Stoboclo is supplied as a clear, colorless to slightly yellow, essentially particle-free solution. The pre-filled syringe is made of Type 1 borosilicate glass with a stainless-steel needle and a protective needle cap. A needle-safety device is integrated to prevent needle-stick injury after administration. Each carton contains one single-use pre-filled syringe. Once administered, the syringe must be disposed of as sharps waste and must not be reused.